Sulfonylurea Compounds
"Sulfonylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D013453
|
MeSH Number(s) |
D02.886.590.795 D02.948.828
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Sulfonylurea Compounds".
This graph shows the total number of publications written about "Sulfonylurea Compounds" by people in this website by year, and whether "Sulfonylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 2 | 3 | 1996 | 1 | 0 | 1 | 1999 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2006 | 2 | 0 | 2 | 2008 | 0 | 3 | 3 | 2009 | 0 | 1 | 1 | 2010 | 1 | 2 | 3 | 2011 | 0 | 2 | 2 | 2012 | 1 | 0 | 1 | 2013 | 0 | 3 | 3 | 2014 | 1 | 1 | 2 | 2015 | 2 | 0 | 2 | 2017 | 2 | 1 | 3 | 2019 | 0 | 1 | 1 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonylurea Compounds" by people in Profiles.
-
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ. 2022 10 03; 379:e070717.
-
Letourneau LR, Greeley SAW. Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations. Curr Diab Rep. 2019 06 27; 19(8):52.
-
Lemelman MB, Letourneau L, Greeley SAW. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol. 2018 03; 45(1):41-59.
-
Lanning MS, Carmody D, Szczerbinski L, Letourneau LR, Naylor RN, Greeley SAW. Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures. Pediatr Diabetes. 2018 05; 19(3):393-397.
-
Greeley SA, Zielinski MC, Poudel A, Ye H, Berry S, Taxy JB, Carmody D, Steiner DF, Philipson LH, Wood JR, Hara M. Preservation of Reduced Numbers of Insulin-Positive Cells in Sulfonylurea-Unresponsive KCNJ11-Related Diabetes. J Clin Endocrinol Metab. 2017 01 01; 102(1):1-5.
-
Thurber BW, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia. 2015 Jul; 58(7):1430-5.
-
Greeley SA. Response letter to the editor. J Clin Endocrinol Metab. 2015 Jan; 100(1):L14.
-
Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014 Dec; 99(12):E2709-14.
-
Ogata H, Seino Y, Harada N, Iida A, Suzuki K, Izumoto T, Ishikawa K, Uenishi E, Ozaki N, Hayashi Y, Miki T, Inagaki N, Tsunekawa S, Hamada Y, Seino S, Oiso Y. KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol. 2014 Aug; 222(2):191-200.
-
Philla KQ, Bauer AJ, Vogt KS, Greeley SA. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation. Diabetes Care. 2013 Dec; 36(12):e201.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|